A detailed history of Hudson Canyon Capital Management transactions in Eli Lilly & CO stock. As of the latest transaction made, Hudson Canyon Capital Management holds 4,683 shares of LLY stock, worth $4.29 Million. This represents 2.87% of its overall portfolio holdings.

Number of Shares
4,683
Previous 5,354 12.53%
Holding current value
$4.29 Million
Previous $4.17 Billion 1.79%
% of portfolio
2.87%
Previous 2.68%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$724.87 - $909.04 $486,387 - $609,965
-671 Reduced 12.53%
4,683 $4.24 Billion
Q4 2023

Jan 26, 2024

SELL
$525.19 - $619.13 $63,547 - $74,914
-121 Reduced 2.21%
5,354 $3.12 Billion
Q3 2023

Nov 14, 2023

SELL
$434.7 - $599.3 $224,739 - $309,838
-517 Reduced 8.63%
5,475 $2.94 Billion
Q2 2023

Aug 02, 2023

SELL
$350.74 - $468.98 $66,640 - $89,106
-190 Reduced 3.07%
5,992 $2.81 Billion
Q1 2023

Aug 02, 2023

SELL
$310.63 - $364.82 $10,250 - $12,039
-33 Reduced 0.53%
6,182 $2.12 Billion
Q4 2022

Aug 02, 2023

SELL
$321.55 - $374.67 $252,416 - $294,115
-785 Reduced 11.21%
6,215 $2.27 Billion
Q3 2022

Aug 02, 2023

SELL
$296.48 - $337.87 $118,592 - $135,148
-400 Reduced 5.41%
7,000 $2.26 Billion
Q2 2022

Aug 02, 2023

SELL
$278.73 - $327.27 $420,046 - $493,195
-1,507 Reduced 16.92%
7,400 $2.4 Billion
Q4 2021

Aug 02, 2023

SELL
$224.85 - $279.04 $99,383 - $123,335
-442 Reduced 4.73%
8,907 $2.46 Billion
Q3 2021

Aug 02, 2023

SELL
$221.6 - $272.71 $77,781 - $95,721
-351 Reduced 3.62%
9,349 $2.16 Billion
Q2 2021

Aug 02, 2023

SELL
$180.55 - $233.54 $134,148 - $173,520
-743 Reduced 7.11%
9,700 $2.23 Billion
Q1 2021

Aug 02, 2023

SELL
$164.32 - $212.72 $160,047 - $207,189
-974 Reduced 8.53%
10,443 $1.95 Billion
Q4 2020

Aug 02, 2023

BUY
$130.46 - $172.63 $1.49 Million - $1.97 Million
11,417 New
11,417 $1.93 Billion

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $869B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Hudson Canyon Capital Management Portfolio

Follow Hudson Canyon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Canyon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Canyon Capital Management with notifications on news.